Jennifer Stevens sold $45k of TLSI
Chief Regulatory Officer at TriSalus Life Sciences, Inc.. 8,704 shares at an average of $5.18, traded May 19, 2025, filed May 21, 2025.
Score components
- +15RoleOfficer
- +6Trade size$45k at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001826667-25-000053, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2025 | AGrant or award Common Stock | +28,455 | $5.18 | $147k | 86,344 | May 21, 2025 |
| May 19, 2025 | SOpen-market sale Common Stock | -8,704 | $5.18 | $45k | 77,640 | May 21, 2025 |
Related signals
Other insiders at TriSalus Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $1,299 296 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,427 325 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $1,387 316 shares | -0% | |
| 23Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $13k 3,184 shares | -2% | |
| 23Weak | TriSalus Life Sciences, Inc. | Jodi Devlin Chief of Clinical Operations | $13k 3,207 shares | -3% | |
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $25k 4,764 shares | -4% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jodi Devlin Chief of Clinical Operations | $25k 4,764 shares | -8% | |
| 36Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $34k 6,597 shares | -9% | |
| 15Weak | TLSIsell TriSalus Life Sciences, Inc. | Bryan F. Cox CHIEF SCIENTIFIC & MANUFACT. | $1,394 314 shares | -0% | |
| 20Weak | TLSIbuy TriSalus Life Sciences, Inc. | Frankenius Equity AB owner | $250k 62,972 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.